PARP1 and familial pancreatic carcinoma: In conclusion, basic research into DNA damage repair biochemistry led to the identification of PARP, the inhibition of which, almost 40 years later, is showing great promise in the treatment of BRCA-deficient ovarian, breast, prostate and pancreatic cancer patients [87,88,89].